Nemus hires Catalent to formulate second chemo-induced nausea drug

By Gareth Macdonald contact

- Last updated on GMT

iStock/emiliozv
iStock/emiliozv

Related tags: Cannabis

Catalent Pharma Solutions has been hired to formulate Nemus Bioscience’s synthetic cannabinoid based chemotherapy induced nausea drug.

The US contract manufacturing organisation (CMO) will formulate NB1222​ - a synthetic tetrahydrocannabinol (THC) prodrug – into suppositories for use in upcoming clinical trials in cancer patients suffering chemotherapy-induced nausea and vomiting (CINV).

Nemus CEO Brian Murphy told us "Catalent has performed a chemical feasibility assessment related to compatibility of materials.  The companies plan to move forward to develop prototype materials and test those for the typical parameters associated with suppository delivery of drug before human exposure​."

The work will be carried out by Catalent Softgel Technologies according to division president Aris Gennadios.

Gennadios said: “With the convenience that softgel can offer, combined with a lipid formulation to enhance bioavailability and help assure dose uniformity, we expect Nemus to be well positioned to pursue development of an efficacious drug product​.”

The project is the second Catalent has taken on for Nemus.

Last January Nemus announced it had hired the CMO to begin developing a formulation of another CINV candidate called NB2111​.

Synthetic drug

The synthetic cannabinoid candidates are made using an in-vitro​ synthetic manufacturing method developed by Teewinot Life Sciences.

The technology – which Nemus licensed last year - uses cultured yeast or E.coli cells to produce enzymes called THCA synthase and CBDA synthase that are used to make the drug actives.

At the time Murphy said the approach allows cannabinoids to be made much faster than traditional plant-based production.

"Tweewinot will offer Nemus a strategic and competitive advantage in the cannabinoid therapeutic marketplace by enabling our proprietary THC prodrug and unique CBD derivative molecules to be manufactured in a time-efficient manner​” he said.

He also predicted the licensed method will allow Nemus to reduce its manufacturing costs by 60-70% and praised the range of cannabinoids that can be produced.

We are impressed with the versatility of the biosynthesis system in the ability to produce an array of cannabinoids, which fits plans for our library of cannabinoid pipeline molecules developed with our research and commercialization partner, the University of Mississippi​."

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more